chart looking attractive !, page-12

Getting a drug to market isn't free or cheap. As mentioned by the company previously, the intial stages of phase III is more cash-flow demanding than the later stages.

We all live in hope of a partnership deal - but the extra cash from the cap raising has given them a 12mth lifeline, so now they can accept the best deal, not be desperate for just any deal.

Great drug, surely this won't be a problem...